Lymphoma Working Party (LWP)
Study type:
Study number:
2022-R-01
Type of Stem Cell Treatment:
Allogeneic
CAR T
Diseases:
Non-Hodgkin’s Lymphoma (NHL)
Short title:
Primary objective:
Progression Free Survival (PFS) and Overall Survival (OS) at 2 years from transplant
Incidence of relapse (IR), NRM
Incidence of relapse (IR), NRM
Key inclusion criteria:
Country:
All EBMT member countries
Principal investigator:
Simon Renders, MD
EBMT Study coordinator:
Hervé Finel
Reason for processing personal data:
Patients’ data is needed to be able to identify the patient and calculate age at any time (impact on SAEs and response to clinical medications). Health care personal data is part of the CV collected for evidence of proper qualification for running the trial.
Categories of personal data collected:
Medical data already reported to the EBMT Registry
Study Specific Questionnaire (MED-C)
Recipients who may access the data:
Paris Study Unit
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No
Privacy notices
Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)
Data Protection Impact Assessments
Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results